Oragenics, Inc. Provides Update on Its Drug Intended for the Treatment of Concussion and Non-Compliance with NYSE American Continued Listing Standards Page 1

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN) (“the Company”), a company focused on the development of unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and significant business progress for 2024. The Company continues to execute on its business strategy to develop and advance its lead candidate, ONP-002, for the treatment of concussion. Phase 2 human trials are planned with the expectation of initiating in the fourth quarter of this year.

Performance: